Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 10:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 4,257 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Peripheral Blood Collection Clear all
Recruiting Not applicable Interventional

Real-Time Levodopa Level Monitoring in Parkinson Disease

NCT04735627
View directory record Official record
Conditions
Parkinson Disease
Interventions
Levodopameter
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
40 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Oct 31, 2026, 10:15 AM EDT
Withdrawn Phase 1 Interventional

²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma

NCT04579523
View directory record Official record
Conditions
Multiple Myeloma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Cyclophosphamide, Fludarabine Phosphate, Total-Body Irradiation, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, X-Ray Imaging
Procedure · Biological · Drug + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 31, 2026, 10:15 AM EDT
Completed No phase listed Observational

Evaluation of Biomarker Kinetics After Mild Brain Injury Trauma

NCT02541123
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Blood draw
Other
Lead sponsor
Banyan Biomarkers, Inc
Industry
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Gainesville, Florida • Orlando, Florida • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Oct 31, 2026, 10:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Proteomics of Brain Trauma-associated Elevated Intracranial Pressure (ICP)

NCT00178659
View directory record Official record
Conditions
Brain Injuries, Traumatic, Traumatic Brain Injury
Interventions
Blood/saliva samples for protein/molecular analysis
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
14 Years to 65 Years
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 31, 2026, 10:15 AM EDT
Recruiting Phase 2 Interventional

Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma

NCT05001880
View directory record Official record
Conditions
Peritoneal Malignant Mesothelioma
Interventions
Atezolizumab, Bevacizumab, Biospecimen Collection, Carboplatin, Computed Tomography, Cytoreductive Surgery, Hyperthermic Intraperitoneal Chemotherapy, Pemetrexed Disodium, Positron Emission Tomography
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
41
States / cities
Phoenix, Arizona • Chicago, Illinois • Danville, Illinois + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 31, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia

NCT00553202
View directory record Official record
Conditions
Leukemia
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, methotrexate, methylprednisolone, tacrolimus, laboratory biomarker analysis, pharmacological study, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation
Biological · Drug · Other + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
48
States / cities
Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 45 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Oct 31, 2026, 10:15 AM EDT
Active, not recruiting Phase 1 Interventional

Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies

NCT04732845
View directory record Official record
Conditions
Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia
Interventions
Fully human anti CD19 CAR-T Cell Dose, Fludarabine, Cyclophosphamide
Biological · Drug
Lead sponsor
Benjamin Tomlinson
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2040
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 31, 2026, 10:15 AM EDT
Completed No phase listed Observational

Evaluation of Multiple Protein and Molecular Biomarkers to Estimate Risk of Cancer in Gynecology Patients Presenting With a Pelvic Mass.

NCT02781272
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
Pelvic imaging, Blood draw, Imaging guided biopsy, surgical biopsy or surgical excision
Procedure
Lead sponsor
Angle plc
Industry
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 31, 2026, 10:15 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Will Hydroxychloroquine Impede or Prevent COVID-19

NCT04341441
View directory record Official record
Conditions
COVID-19, Coronavirus, Coronavirus Infections, SARS-CoV 2
Interventions
Hydroxychloroquine - Daily Dosing, Hydroxychloroquine - Weekly Dosing, Placebo oral tablet, Monitoring Visit - Baseline, Monitoring Visit - Week 4, Monitoring Visit - Week 8, Weekly Assessment
Drug · Other · Diagnostic Test
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 75 Years
Enrollment
624 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 31, 2026, 10:15 AM EDT
Recruiting No phase listed Observational

Biology of Young Lung Cancer Study: The YOUNG LUNG Study

NCT05265429
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Small Cell Lung Carcinoma, NUT Carcinoma
Interventions
Data and Specimen Collection
Genetic
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
15 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 31, 2026, 10:15 AM EDT
Active, not recruiting Early Phase 1 Interventional

EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

NCT06011772
View directory record Official record
Conditions
Colo-rectal Cancer
Interventions
Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine, Leucovorin, Oxaliplatin, Fluorouracil, Bevacizumab, Irinotecan, Cetuximab, Metastasectomy, Biospecimen collection, Computed Tomography, Panitumumbab
Biological · Drug · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 31, 2026, 10:15 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer

NCT02314169
View directory record Official record
Conditions
Anal Canal Squamous Cell Carcinoma, Metastatic Anal Canal Carcinoma, Stage IV Anal Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
55
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 31, 2026, 10:15 AM EDT
Completed No phase listed Observational

Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening

NCT03372902
View directory record Official record
Conditions
Breast Cancer, Breast Benign
Interventions
Breast MRI, Breast Mammogram, Blood draw, Breast Biopsy, online participant reported questionnaire
Device · Other · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
7
States / cities
Hartford, Connecticut • Miami, Florida • Basking Ridge, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 31, 2026, 10:15 AM EDT
Completed No phase listed Observational

Predicting Disease Progression and/or Recurrence in Cancer

NCT04776837
View directory record Official record
Conditions
Patient Reported Outcome Measures, Colorectal Cancer, Pancreatic Cancer, Biliary Tract Cancer, Esophageal Cancer, Metastatic Cancer, Disease Progression, Survival Analysis
Interventions
Observational Cohort
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 31, 2026, 10:15 AM EDT
Recruiting Early Phase 1 Interventional

Medication Combinations of Dasatinib, Quercetin, Fisetin, Temozolomide, LMP744, and Autologous TLPO Vaccine for the Treatment of Previously Treated Glioma With Residual Disease

NCT07025226
View directory record Official record
Conditions
Glioma
Interventions
Biospecimen Collection, Dasatinib, Fisetin, Magnetic Resonance Imaging, Patient Observation, Positron Emission Tomography, Quercetin, Temozolomide, Topoisomerase-1 Inhibitor LMP744, Single Agent Therapy
Procedure · Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 31, 2026, 10:15 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Feasibility and Acceptability of Remote Saliva Collection

NCT07884474
View directory record Official record
Conditions
Survivors of Childhood Cancer, Acute Lymphoblastic Leukemia, Childhood
Interventions
Salivary Cortisol Collection, Blood Biomarker Collection, Hair Cortisol Collection, Nail Cortisol Collection, WatchPAT Sleep Assessment, Morning and Evening Diaries, MEMS Cap Adherence Monitoring, OnTimePoint Application, Survey and Questionnaire Assessment
Diagnostic Test · Behavioral · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
8 Years to 18 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 31, 2026, 10:15 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Neutrophil Extracellular Traps Formation in Breast Cancer Patients Taking Tamoxifen

NCT05056857
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Biospecimen Collection, Electronic Health Record Review
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
290 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 31, 2026, 10:15 AM EDT
Active, not recruiting Phase 2 Interventional

Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment

NCT05859334
View directory record Official record
Conditions
Recurrent Glioma, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma, Recurrent WHO Grade 4 Glioma
Interventions
Biospecimen Collection, Erdafitinib, Magnetic Resonance Imaging, Optical Coherence Tomography
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
27
States / cities
Aurora, Colorado • Coral Gables, Florida • Deerfield Beach, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 31, 2026, 10:15 AM EDT
Recruiting No phase listed Observational

Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders

NCT00830557
View directory record Official record
Conditions
Islet Cell Tumor, Pancreatic Cancer, Pancreatic Disease, Acute Pancreatitis, Chronic Pancreatitis, Hereditary Pancreatitis, Pancreatic Neuroendocrine Carcinoma, Pancreatic Adenocarcinoma
Interventions
medical chart review, survey administration, biospecimen collection
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2027
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 31, 2026, 10:15 AM EDT
Completed Phase 4 Interventional Results available

The Role of Acute Combined PPAR Alpha and Gamma Stimulation on Insulin Action in Humans

NCT00179400
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Pioglitazone, Placebo, Pancreatic Clamp Study
Drug · Procedure
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 31, 2026, 10:15 AM EDT
Recruiting Phase 1 Interventional

PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

NCT05234307
View directory record Official record
Conditions
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Adenosine A2B Receptor Antagonist PBF-1129, Biospecimen Collection, Nivolumab
Drug · Procedure · Biological
Lead sponsor
Dwight Owen
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 31, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma

NCT02098109
View directory record Official record
Conditions
Multiple Myeloma, Lymphoma, Non-Hodgkin
Interventions
XM02 Filgrastim, Filgrastim, Apheresis, Plerixafor, Stem Cell Transplant
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Oct 31, 2026, 10:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Reduction of Peanut Reactivity and Immune Modulation With Anti-IgE Therapy

NCT02194530
View directory record Official record
Conditions
Peanut Allergy
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Oct 31, 2026, 10:15 AM EDT
Completed Phase 1 Interventional

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

NCT04477512
View directory record Official record
Conditions
Metastatic Hormone Refractory Prostate Cancer
Interventions
Cabozantinib, Nivolumab, Abiraterone acetate, Prednisone, Peripheral blood collection
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 31, 2026, 10:15 AM EDT